US2018325994A1PendingUtilityA1

Anti-bacterial compositions for drug administration

70
Assignee: AEGIS THERAPEUTICS LLCPriority: Aug 25, 2004Filed: Jul 24, 2018Published: Nov 15, 2018
Est. expiryAug 25, 2024(expired)· nominal 20-yr term from priority
A61K 31/4439A61K 9/08A01N 43/16A61K 38/12A61K 38/29A61K 31/70A61K 47/183A61K 9/0048Y02A50/473A61K 47/26A61K 9/0043A01N 33/08Y02A50/30
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of inhibiting microbial growth in an aqueous pharmaceutical composition comprising, admixing:
 a) at least one alkylsaccharide having antibacterial activity, wherein the alkylsaccharide consists of an alkyl chain length from 12 to 14 carbon atoms linked by glycosidic linkage to a maltose;   b) at least one therapeutic peptide, wherein the therapeutic peptide is octreotide or variant thereof; and   c) ethylenediaminetetraacetic acid (EDTA) or a salt thereof.   
     
     
         2 . The method of  claim 1 , wherein the alkylsaccharide is selected from the group consisting of n-Dodecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside and n-tetradecyl-4-O-α-D-glucopyranosyl-β-D-glucopyranoside. 
     
     
         3 . The method of  claim 1 , wherein the concentration of the alkylsaccharide is about 0.05% to 0.5% by weight. 
     
     
         4 . The method of  claim 1 , wherein the concentration of alkylsaccharide is about 0.125% to 0.25% by weight. 
     
     
         5 . The method of  claim 1 , wherein the concentration of EDTA is from about 0.01% to 2% by weight. 
     
     
         6 . The method of  claim 1 , wherein the pH is about 7.0 or less. 
     
     
         7 . The method of  claim 1 , wherein the composition is formulated for administration transmucosally, transdermally, optically, or by injection. 
     
     
         8 . The method of  claim 1 , wherein microbial growth is inhibited of  Candida albicans, Aspergillus brasiliensis  ( Aspergillus niger ),  Escherichia coli, Staphylococcus aureus , or  Pseudomonas aeruginosa.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.